ClinicalTrials.gg
CompletedNCT01034462Updated Oct 25, 2013Results posted

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

A Phase 3 interventional study of Levomilnacipran ER and Placebo in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 23 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-10-25.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
8th of 14
442 · median 472
Started
2009
with 3 others
Phase 3
10 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
9 of 14
Forest Laboratories

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 8th largest by enrollment, is one of 4 that started in 2009, is one of 10 in phase 3, and was the 3rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18-80 years old
  • Currently meet the criteria for Major Depressive Disorder
  • The patient's current depressive episode must be at least 4 weeks in duration

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women with who are not practicing a reliable method of .
  • Patients with a history of meeting criteria for: a. any manic or hypomanic episode; b. schizophrenia or any other psychotic disorder; c. obsessive-compulsive disorder.
  • Patients who are considered a suicide risk
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
442 participants (actual)

Study arms

  • Experimental
    1

    Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.

    Drug: Levomilnacipran ER

  • Placebo comparator
    2

    Matching placebo capsules, oral administration, once daily dosing.

    Drug: Placebo

Interventions

  • Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks

  • DrugPlacebo

    Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity).

    Time frame: From Baseline to Week 8

Secondary outcomes

  1. Change in Sheehan Disability Scale (SDS) Total Score

    The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)

    Time frame: From Baseline to Week 8

07

Results

Posted Oct 25, 2013

Participant flow

Patient were recruited over a 21-month period from December of 2009 to September of 2011 at 23 studies sites in the United States.

Participant flow — Overall Study
MilestonePlaceboLevomilnacipran ER
Started217217
Completed172163
Not completed4554
Withdrew: Adverse event717
Withdrew: Lack of efficacy44
Withdrew: Protocol violation107
Withdrew: Withdrawal by subject98
Withdrew: Lost to follow-up1416
Withdrew: Other reasons12

Outcome measures

PrimaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity).

Time frame:
From Baseline to Week 8
Reported as:
Least squares mean · units on a scale
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
units on a scalePlaceboLevomilnacipran ER
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-12.2 ± 0.78-15.3 ± 0.79
Statistical analysis
  • Placebo · Mixed Models Analysis · p = 0.0051 · Least squares mean difference: -3.095 · 95% CI -5.256 to -0.935Mixed-effects model for repeated measures.
SecondaryChange in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)

Time frame:
From Baseline to Week 8
Reported as:
Least squares mean · units on a scale
Change in Sheehan Disability Scale (SDS) Total Score
units on a scalePlaceboLevomilnacipran ER
Change in Sheehan Disability Scale (SDS) Total Score-5.4 ± 0.57-8.0 ± 0.58
Statistical analysis
  • Placebo vs Levomilnacipran ER · Mixed Models Analysis · p = 0.0010 · Least squares mean difference: -2.632 · 95% CI -4.193 to -1.070Mixed-effects model for repeated measures.

Adverse events

Collected over Adverse event data was collection over a 25-month period from December 2009 to January 2012 at 23 study sites in the U.S.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/217 (1.4%)79/217 (36.4%)
Levomilnacipran ER—4/217 (1.8%)151/217 (69.6%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboLevomilnacipran ER
HypertensionVascular disorders0/2172/217
Suicidal ideationPsychiatric disorders0/2172/217
Non-cardiac chest painGeneral disorders1/2171/217
Head injuryInjury, poisoning and procedural complications1/2170/217
Road traffic accidentInjury, poisoning and procedural complications1/2171/217
Traumatic liver injuryInjury, poisoning and procedural complications1/2170/217
AsthmaRespiratory, thoracic and mediastinal disorders1/2170/217
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/2170/217
Intentional overdoseInjury, poisoning and procedural complications0/2171/217
Suicide attemptPsychiatric disorders0/2171/217
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboLevomilnacipran ER
NauseaNervous system disorders8/21747/217
HeadacheNervous system disorders27/21738/217
DizzinessNervous system disorders7/21728/217
Dry mouthGastrointestinal disorders24/21727/217
ConstipationGastrointestinal disorders8/21722/217
TachycardiaCardiac disorders6/21718/217
Urinary hesitationRenal and urinary disorders0/21717/217
HyperhidrosisSkin and subcutaneous tissue disorders4/21715/217
InsomniaPsychiatric disorders5/21715/217
DiarrhoeaGastrointestinal disorders12/21714/217

Baseline characteristics

While 442 patients were randomized to receive double-blind treatment, 8 of these patients discontined before receiving double-blind treatment. The Baseline Participant population is based on the 434 randomized patients who went on to receive double-blind treatment (Safety Population).

Age Continuous
Age Continuous(years)PlaceboLevomilnacipran ERTotal
Mean44.6 ± 13.945.0 ± 13.244.8 ± 13.5
Age, Customized
Age, Customized(participants)PlaceboLevomilnacipran ERTotal
18 years to 19 years224
20 years to 29 years383472
30 years to 39 years374481
40 years to 49 years514091
50 years to 59 years5768125
60 years to 80 years322961
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLevomilnacipran ERTotal
Female143140283
Male7477151
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLevomilnacipran ERTotal
White182177359
Black or African American283361
Asian224
American Indian or Alaska native112
Other448
Hispanic or Latino172138
Not Hispanic or Latino200196396
Region of Enrollment
Region of Enrollment(participants)PlaceboLevomilnacipran ERTotal
United States217217434
Weight
Weight(kg)PlaceboLevomilnacipran ERTotal
Mean84.58 ± 18.1584.47 ± 18.9884.52 ± 18.55
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilograms Per Meter Squared)PlaceboLevomilnacipran ERTotal
Mean29.60 ± 5.3029.20 ± 5.4529.40 ± 5.37
08

Study locations

23 sites
  • Forest Investigative Site 055
    Dothan, Alabama 36305, United States
  • Forest Investigative Site 065
    Highlands Ranch, Colorado 80130, United States
  • Forest Investigative Site 057
    Boca Raton, Florida 33431, United States
  • Forest Investigative Site 060
    Boca Raton, Florida 33432, United States
  • Forest Investigative Site 064
    Gainesville, Florida 32607, United States
  • Forest Investigative Site 053
    Ocala, Florida 34471, United States
  • Forest Investigative Site 061
    Orlando, Florida 32806, United States
  • Forest Investigative Site 059
    Winter Park, Florida 32789, United States
  • Forest Investigative Site 070
    Atlanta, Georgia 30328, United States
  • Forest Investigative Site 066
    Smyrna, Georgia 30080, United States
  • Forest Investigative Site 072
    Chicago, Illinois 60634, United States
  • Forest Investigative Site 050
    Oakbrook, Illinois 60523, United States
  • Forest Investigative Site 063
    Indianapolis, Indiana 46260, United States
  • Forest Investigative Site 071
    Prairie Village, Kansas 66206, United States
  • Forest Investigative Site 052
    Shreveport, Louisiana 71104, United States
  • Forest Investigative Site 051
    Brooklyn, New York 11214, United States
  • Forest Investigative Site 056
    Oklahoma City, Oklahoma 73112, United States
  • Forest Investigative Site 067
    Oklahoma City, Oklahoma 73112, United States
  • Forest Investigative Site 058
    Salem, Oregon 97301, United States
  • Forest Investigative Site 054
    Allentown, Pennsylvania 18104, United States
  • Forest Investigative Site 062
    San Antonio, Texas 78229, United States
  • Forest Investigative Site 068
    Virginia Beach, Virginia 23452, United States
  • Forest Investigative Site 069
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Wesnes KA, Gommoll C, Chen C, Sambunaris A, McIntyre RS, Harvey PD. Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study. Int Clin Psychopharmacol. 2017 Mar;32(2):72-79. doi: 10.1097/YIC.0000000000000157. PubMed 27861191 ↗
  • Cutler AJ, Gommoll CP, Chen C, Greenberg WM, Ruth A. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories. Prim Care Companion CNS Disord. 2015 Jun 11;17(3):10.4088/PCC.14m01753. doi: 10.4088/PCC.14m01753. eCollection 2015. PubMed 26644957 ↗
  • Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014 Feb;34(1):47-56. doi: 10.1097/JCP.0000000000000060. PubMed 24172209 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 10 months after primary completion. A results delay was requested in Dec 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2009
First posted
Dec 17, 2009
Start
Dec 2009
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results delay requested
Dec 30, 2011
Results first posted
Oct 25, 2013
Last update
Oct 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01034462
Responsible party
Sponsor
First posted
Dec 17, 2009
Start date
Dec 2009
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Oct 25, 2013
Last update
Oct 25, 2013

Study contacts

Carl Gommoll, MS
study director · Forest Research Institute, a subsidiary of Forest Laboratories Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion